Raymond James Financial Inc. Purchases New Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Raymond James Financial Inc. purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 70,826 shares of the specialty pharmaceutical company's stock, valued at approximately $3,916,000. Raymond James Financial Inc. owned approximately 0.34% of ANI Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in ANIP. JPMorgan Chase & Co. boosted its stake in ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock valued at $33,101,000 after buying an additional 340,854 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of ANI Pharmaceuticals by 14.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company's stock valued at $854,000 after acquiring an additional 1,972 shares during the last quarter. Geode Capital Management LLC increased its position in shares of ANI Pharmaceuticals by 4.2% in the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company's stock worth $25,373,000 after purchasing an additional 17,314 shares during the last quarter. Barclays PLC increased its position in shares of ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock worth $8,534,000 after purchasing an additional 135,003 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in shares of ANI Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company's stock worth $705,000 after purchasing an additional 691 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of the firm's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the completion of the transaction, the vice president now owns 80,145 shares in the company, valued at approximately $5,526,799.20. This trade represents a 0.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,200 shares of company stock valued at $197,792 in the last quarter. 11.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Truist Financial increased their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a report on Monday, April 21st. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price on the stock. Guggenheim reiterated a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, April 11th. HC Wainwright reiterated a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Finally, StockNews.com cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Stock Up 1.5 %

Shares of NASDAQ:ANIP traded up $1.03 during midday trading on Friday, reaching $71.72. The company's stock had a trading volume of 92,779 shares, compared to its average volume of 280,523. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a 50 day moving average of $65.24 and a 200-day moving average of $60.22. The firm has a market capitalization of $1.56 billion, a P/E ratio of -130.43 and a beta of 0.49. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $72.57.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.